EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria

Victoria E Stefan, Victoria Klepsch iD, Nikolaus Thuille iD, Martina Steinlechner iD, Sebastian Peer iD, Kerstin Siegmund iD, Peter Lackner, Erich Schmutzhard, Karin Albrecht-Schgör iD, Gottfried Baier iD

Cells · 2025

DOI: 10.3390/cells14151162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Victoria E Stefan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University S…. Hauptthemen laut MEDLINE: Malaria, Cerebral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council Fund, FWF Austrian Science Fund, Austrian Science Fund (FWF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral malaria (CM) is the severe progression of an infection with Plasmodium falciparum, causing detrimental damage to brain tissue and is the most frequent cause of Plasmodium falciparum mortality. The critical role of brain-infiltrating CD8+ T cells in the pathophysiology of CM having been revealed, our investigation focuses on the role of NR2F6, an established immune checkpoint, as a candidate driver of CM pathology. We employed an experimental mouse model of CM based on Plasmodium berghei ANKA (PbA) infection to compare the relative susceptibility of Nr2f6-knock-out and wild-type C57BL6/N mice. As a remarkable result, Nr2f6 deficiency confers a significant survival benefit. In terms of mechanism, we detected less severe endotheliopathy and, hence, less damage to the blood–brain barrier (BBB), accompanied by decreased sequestered parasites and less cytotoxic T-lymphocytes within the brain, manifesting in a better disease outcome. We present evidence that NR2F6 deficiency renders mice more resistant to experimental cerebral malaria (ECM), confirming a causal and non-redundant role for NR2F6 in the progression of ECM disease. Consequently, pharmacological inhibitors of the NR2F6 pathway could be of use to bolster BBB integrity and protect against CM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, CerebralAnimalsMiceBlood-Brain BarrierMice, Inbred C57BLDisease Models, AnimalPlasmodium bergheiMice, KnockoutBrainCD8-Positive T-Lymphocytes

Stichwörter der Autor:innen

CD8+ T cell brain infiltrationcompromised blood–brain barrier (BBB) integrityexperimental cerebral malaria (ECM)group Finnovative pharmacological therapy solution for CMmember 6 (NR2F6)nuclear receptor subfamily 2

Autor:innen und Institutionen

  • Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University Salzburg, 5020 Salzburg, Austria.
  • Department of Biosciences and Medical Biology, University of Salzburg, 5020 Salzburg, Austria.
  • Institute for Cell Genetics, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Vienna Healthcare Group, Department of Neurology, Klinik Floridsdorf, 1010 Vienna, Austria.
  • Karl-Landsteiner-Institute for Clinical Research in Acute Neurology, 1010 Vienna, Austria.

ORCID-Profile: Victoria Klepsch, Nikolaus Thuille, Martina Steinlechner, Sebastian Peer, Kerstin Siegmund, Karin Albrecht-Schgör, Gottfried Baier

Förderung

  • European Research Council Fund
  • FWF Austrian Science Fund
  • Austrian Science Fund (FWF)

Zitieren

APA

Stefan, V. E., Klepsch, V., Thuille, N., Steinlechner, M., Peer, S., Siegmund, K., Lackner, P., Schmutzhard, E., Albrecht-Schgör, K., & Baier, G. (2025). NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria. Cells. https://doi.org/10.3390/cells14151162

Vancouver

Stefan VE, Klepsch V, Thuille N, Steinlechner M, Peer S, Siegmund K, et al. NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria. Cells. 2025. doi:10.3390/cells14151162

BibTeX
@article{Stefan2025,
  author = {Stefan, Victoria E and Klepsch, Victoria and Thuille, Nikolaus and Steinlechner, Martina and Peer, Sebastian and Siegmund, Kerstin and Lackner, Peter and Schmutzhard, Erich and Albrecht-Schgör, Karin and Baier, Gottfried},
  title = {NR2F6 as a Disease Driver and Candidate Therapeutic Target in Experimental Cerebral Malaria},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14151162}
}
Kostenlos starten →